Sanuwave Health posts Q3 2026 revenue decline and operating loss amid CMS rule disruption

Sanuwave Health reported third‑quarter 2026 revenue of $8.6 million, down about 24% year‑over‑year, and a swing to an operating loss of $1.1 million from a $0.9 million operating profit in the prior year. System sales collapsed 74% to 40 units, while consumables revenue grew modestly. Management cited a proposed CMS rule change as a major headwind to the wound‑care market.

The sharp revenue drop and operating loss reduce near‑term earnings visibility, but the company’s cash balance of $6.6 million provides liquidity to navigate the disruption. Shares rose 8.51% in pre‑market trading, indicating investor focus on the longer‑term hospital strategy despite the short‑term setbacks.

  • 1Revenue fell 24% year‑over‑year to $8.6 million in Q3 2026.
  • 2GAAP EPS was –$0.16 for the quarter.
  • 3Operating loss was $1.1 million, reversing a $0.9 million operating income in Q3 2025.
  • 4System sales dropped to 40 units, a 74% decline from 155 units a year earlier.
  • 5Consumables revenue grew 2% year‑over‑year to approximately $6.8 million.
  • 6Cash and cash equivalents were $6.6 million as of September 30, 2026.

Sources